Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Saturday. The firm issued a sell rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.35 on Friday. The firm has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $0.80. The stock has a market cap of $4.27 million, a price-to-earnings ratio of -0.05 and a beta of 0.43. Oragenics has a 1-year low of $0.25 and a 1-year high of $7.74.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.